How domestic pharma manufacturing became central to America’s agenda
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
The United States remains heavily reliant on foreign sources for the production of active pharmaceutical ingredients (APIs) and finished dosage forms of essential medicines. For years, this dependency was seen as a cost-efficient strategy. However, global shocks such as the COVID-19 pandemic, the war in Ukraine, and rising tensions with China have exposed the fragility of this model. The Food and Drug Administration reports that 78 percent of API manufacturers supplying the American market operate overseas, and a significant share are based in China and India.
Estimates from Brookings suggest that around 25 percent of APIs in US-consumed medicines originate in China, though the actual number may be higher due to opaque international supply chains. Many of the chemical precursors essential to drug manufacturing also come from Chinese factories, which makes even basic reshoring efforts vulnerable to upstream disruptions.
What began as a cost-saving business practice has now escalated into a national security issue. The Department of Health and Human Services has identified recurring drug shortages affecting everything from antibiotics to cancer treatments. These shortages often stem from supply chain breakdowns linked to over-concentration of production in a limited number of offshore facilities.
The US pharmaceutical supply chain has become both strategically brittle and economically risky. This is no longer just a concern for the healthcare industry. It is now a broader issue tied to public health preparedness and national resilience.
The strategic and policy drivers for reshoring drug manufacturing
What was once a marginal economic concern has become a core bipartisan strategy. Policymakers from both parties are calling for increased domestic production of pharmaceuticals as part of a push for economic sovereignty. The Biden administration and congressional Republicans alike are framing domestic drug manufacturing as critical infrastructure.
One key strategy involves offering tax incentives and grants to drug manufacturers that invest in US-based production. The proposed American Medicines Resilience Act includes provisions to prioritize federal procurement for companies that manufacture essential drugs within the US. The Departments of Defense and Veterans Affairs are also reviewing procurement rules that currently favor the lowest-cost bidders, often foreign suppliers.
In late 2025, the Food and Drug Administration introduced its PreCheck proposal. The initiative is designed to expedite review and certification of new domestic pharmaceutical facilities. Its goal is to eliminate the regulatory backlog that discourages companies from building capacity inside the US.
This strategy is not just about cost or convenience. Lawmakers are increasingly treating drug manufacturing as a counterweight to China’s pharmaceutical influence. China has invested heavily in its biopharmaceutical sector. Some US analysts warn that geopolitical conflict could lead to disruptions or the deliberate withholding of API supplies.
The challenges and timelines of rebuilding domestic pharmaceutical production
While the policy direction is clear, execution remains complex. Rebuilding a robust pharmaceutical manufacturing base in the US will require long-term investments, regulatory coordination, infrastructure, and labor. Analysts suggest that achieving meaningful domestic capacity could take between five and ten years, even under ideal conditions.
Pharmaceutical manufacturing is capital intensive, particularly for sterile injectables, complex generics, and biologics. Construction of a new FDA-compliant facility often exceeds $100 million, with timelines ranging from three to five years before operations begin.
Raw material sourcing presents another obstacle. Many upstream chemical components used to create APIs are no longer made in the US. Moving final-stage production back home does not fully solve supply chain risks if the ingredients still originate abroad.
The labor market adds another layer of difficulty. The US has an ongoing shortage of pharmaceutical engineers, validation specialists, and other skilled technicians. In many rural regions, workforce constraints threaten to slow or limit the impact of new facilities.
Despite these hurdles, the long-term risk of relying on fragile foreign supply chains is increasingly being viewed as greater than the cost of investment. The current shift is less about immediate payoffs and more about securing a stable and responsive drug production system.
Cases and initiatives showing momentum in US medicine manufacturing
Even with the challenges, several initiatives are creating early momentum. Public-private partnerships and federal funding are supporting the growth of domestic medicine production in key regions.
In 2024, Civica Rx, a nonprofit drugmaker, began construction on a $140 million plant in Petersburg, Virginia. The facility is expected to manufacture injectable generics for hospitals and health systems beginning in 2026.
Phlow Corporation received a $354 million federal contract to build a US-based pharmaceutical supply chain focused on essential medicines. The company is working closely with the Biomedical Advanced Research and Development Authority and the Department of Health and Human Services.
States such as North Carolina, Texas, and Indiana are launching local incentive programs to attract pharmaceutical investment. In some cases, these efforts are paired with fast-track zoning approvals and university partnerships aimed at building a long-term talent pipeline.
Community colleges and public universities are also introducing new programs tailored to pharmaceutical manufacturing. These education-to-employment initiatives are designed to provide the technical training necessary to meet industry demand.
While none of these examples is a complete solution, together they represent the early phases of a broader transformation of domestic drug manufacturing.
Success does not require total self-sufficiency. Instead, it requires enough domestic manufacturing capacity to withstand future global disruptions without creating nationwide shortages. Key indicators will include a reduction in essential drug shortages, a diversification of supply chains, and greater procurement from US-based firms by federal health agencies.
If these efforts succeed, the US could improve its public health readiness, create stable jobs, and reduce geopolitical vulnerability. Failure, on the other hand, would leave the country exposed to external shocks and at the mercy of unpredictable global dynamics.
The decisions being made now will shape the future of American healthcare infrastructure. The question is no longer whether domestic production is necessary, but whether the nation is willing to commit the time, resources, and leadership needed to rebuild it.
Sources:
The Washington Times